Love Pharma Inc.: Love Pharma Signs Letter of Intent To Acqu

Love Pharma adding to its addiction treatment portfolio with transdermal IP acquisition for opioid antagonist drug NaltrexoneNaltrexone primarily used to treat alcohol and or opioid use disorder and is

Related Keywords

United States , Canada , United Kingdom , Vancouver , British Columbia , America , Canadian , Zachary Stadnyk , Zach Stadnyk , Neither The Canadian Securities Exchange , Naltrexone Therapeutics Inc , Love Pharma Inc , Canadian Securities Exchange , Pharma Co , Regulation Services Provider , Love Pharma , Naltrexone Therapeutics , Love Pharma President , Private Securities Litigation Reform Act , Love , Dharma , Signs , Setter , Intent , Cquire , Naltrexone , Herapeutics ,